(Published June 2009)
At the conclusion of this activity, participants should be able to:
- Describe the significance of infection with HPV to patients including prevalence, mode of transmission, and long-term consequences.
- Describe three provider-delivered treatments for external genital warts.
- Use national guidelines when screening patients for HPV-related cervical disease.
- Apply evidence-based guidelines when managing abnormal screening tests for cervical cancer, including those specific for adolescents.
- Compare and contrast the bivalent and quadrivalent HPV vaccines.
- Answer frequently asked questions about the clinical use of the HPV vaccines.
Funding for this publication was provided by educational grants from GlaxoSmithKline, Graceway Pharmaceuticals, Merck and Co. Inc., QIAGEN, and Roche Pharmaceuticals.
Don Downing, RPh
Mary Rubin, RNC, PhD, CRNP
Richard Guido, MD
This publication is part of a joint Association of Reproductive Health Professionals (ARHP) and Planned Parenthood® Federation of America (PPFA) program that also included the following clinical advisors: Nancy R. Berman, MSN, APRN, BC, Barbara Clark, MPAS, PA-C, Francisco Garcia, MPH, MD, Sherri Sheinfeld Gorin, PhD, Julie Hibben, LMSW, CPSI, Marie Savard, MD, Anafi delia Tavares, MD, Maria Trent, MD, MPH, Jeff Waldman, MD, and Thomas C. Wright, Jr., MD.
Contributing Staff and Consultants
Shama Alam, MScPH, ARHP Education Associate
Jennifer Baldwin, Consulting Designer
Caroline Brown, MPH, MS, MBA, Education Associate
Vanessa Cullins, MD, MPH, MBA, PPFA Vice President for Medical Affairs
Beth Jordan, MD, ARHP Medical Director
Kathryn Quissell, MPH, ARHP Program Manager
Diane Shannon, MD, MPH, Consulting Writer
Wayne C. Shields, ARHP President and CEO
Amy M. Swann, MA, ARHP Director of Education
Jeffrey Waldman, MD, PPFA Senior Director of Clinical Services and Medical Education
Sandy Worthington, MSN, WHNP-BC, CNM, PPFA Program Director
Financial Disclosure Information
The following committee members and/or contributing staff have a financial interest or affiliation with the manufacturers of commercial products possibly related to topics covered in this issue of Clinical Proceedings. These financial interests or affiliations are in the form of grants, research support, speaker support, or other support. This support is noted to fully inform readers and should not have an adverse impact on the information provided within this publication.
Berman: Speaker for QIAGEN Corporation, Graceway Pharmaceuticals, and Merck and Co., Inc.; consultant for QIAGEN Corporation
Clark: Speaker for Ortho Women’s Health and Urology and Wyeth Pharmaceuticals
Cullins: Receives grants and research support from QIAGEN Corporation, Graceway Pharmaceuticals, Merck and Co., Inc., and Ortho Women’s Health, Urology Wyeth Pharmaceuticals; consultant for Merck and Co., Inc.; speaker for Ortho Women’s Health and Urology
Guido: Conducted research for Graceway Pharmaceuticals and Tigress Pharmaceuticals; speaker for Merck and Co., Inc.; consultant for GlaxoSmithKline
Rubin: Speaker for QIAGEN Corporation and Merck and Co., Inc.
Savard: Speaker for QIAGEN Corporation and GlaxoSmithKline
Trent: Speaker for Merck and Co., Inc. Medical Forums
Waldman: Speaker for Q Corporation, Graceway Pharmaceuticals, and GlaxoSmithKline
Wright: Consultant for GlaxoSmithKline, Merck and Co., Inc. and Roche Molecular Systems, Inc.
Alam, Baldwin, Brown, Downing, Garcia, Gorin, Hibben, Jordan, Quissell, Shannon, Shields, Swann, Tavares, and Worthington have no affiliations to disclose.
About Audrey Kelly, PharmD